Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{206463,
        author = {Arshid Rafiq and Hilal Azad and Rutba Maqbool and Summairah Mushtaq},
        title = {Cardiovascular Effects of Diabetes: A Review of Management},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {2},
        pages = {1633-1641},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=206463},
        abstract = {Diabetes mellitus (DM) is a major global public health concern and a well-established independent risk factor for cardiovascular disease (CVD), the leading cause of morbidity and mortality among individuals with diabetes. Persistent hyperglycemia, insulin resistance, endothelial dysfunction, oxidative stress, chronic inflammation, and dyslipidemia collectively contribute to the initiation and progression of cardiovascular complications, including coronary artery disease, heart failure, stroke, peripheral arterial disease, and diabetic cardiomyopathy. These complex pathophysiological mechanisms accelerate atherosclerosis, impair vascular function, and promote adverse cardiac remodeling. This review provides a comprehensive overview of the molecular and cellular mechanisms linking diabetes to cardiovascular disease, with particular emphasis on the roles of chronic hyperglycemia, advanced glycation end products, oxidative stress, endothelial dysfunction, and insulin resistance in cardiovascular injury. In addition, the review summarizes current evidence-based strategies for cardiovascular risk reduction in patients with diabetes, including optimization of glycemic control, blood pressure management, lipid lowering therapy, antiplatelet treatment, and lifestyle modification. Pharmacological advances, particularly the use of sodium glucose cotransporter-2 (SGLT2) inhibitors and other cardioprotective agents, have further improved cardiovascular outcomes in this high-risk population. Early diagnosis, individualized treatment strategies, and comprehensive management of both glycemic status and associated cardiovascular risk factors are essential for reducing cardiovascular morbidity and mortality. A multidisciplinary approach that integrates pharmacological therapy with lifestyle interventions remains the cornerstone of preventing cardiovascular complications and improving long term clinical outcomes in individuals with diabetes.},
        keywords = {},
        month = {July},
        }